

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI BIOLOGICS (CAYMAN) INC.**

**藥明生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2269)**

## **PASSING AWAY OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) was informed that Mr. Teh-Ming Walter Kwauk (“**Mr. Kwauk**”), an independent non-executive Director, the chairman of the audit committee of the Company (the “**Audit Committee**”) and a member of the nomination committee of the Company, passed away on November 24, 2022. Mr. Kwauk had been an independent non-executive Director since 2017. Mr. Kwauk made invaluable contribution to the Company during his tenure of office. The Board would like to express its sincere gratitude to Mr. Kwauk for his dedication and wish to convey its condolences to his family.

Following the passing away of Mr. Kwauk, the Board comprises eight Directors, including two executive Directors, four non-executive Directors and two independent non-executive Directors. As such, the Company is unable to meet the following requirements under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”): (i) the requirement that the Board shall comprise a minimum of three independent non-executive directors, at least one of whom must have appropriate professional qualifications or accounting or related financial management expertise (the “**Relevant Qualification**”), and independent non-executive Directors shall represent at least one-third of the Board under Rules 3.10(1), 3.10(2) and 3.10A of the Listing Rules; and (ii) the requirement that the Audit Committee shall comprise a minimum of three non-executive directors under Rule 3.21 of the Listing Rules, and at least one of whom is an independent non-executive Director with the Relevant Qualification as required under Rule 3.10(2) of the Listing Rules and the Audit Committee must be chaired by an independent non-executive Director.

The Company will endeavor to make the necessary appointment in order to fulfill the requirements of the Listing Rules above and fill the vacancy as soon as practicable, and in any event within the period prescribed under Rules 3.11 and 3.23 of the Listing Rules. The Company will make further announcement(s) as and when appropriate.

By order of the Board  
**WuXi Biologics (Cayman) Inc.**  
**Dr. Ge Li**  
*Chairman*

Hong Kong, November 25, 2022

*As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Ning Zhao, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.*

\* *For identification purpose only*